Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fubotv Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.17 (market cap $29.97B), while Fubotv Inc trades at $9.8 (market cap $1.06B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 28.3× Fubotv Inc's market cap. Which is the better fit depends on your goals.
| ALNY | FUBO | |
|---|---|---|
Market Cap | $29.97B | $1.06B |
Sector | Health | Technology |
52-Week High | $491.22 | $54.72 |
52-Week Low | $205.48 | $8.09 |
Enterprise Value | $27.93B | $1.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
FUBO trades at $9.80, up 1.03% with a bullish technical signal and improving fundamentals. The stock shows strong valuation metrics with P/E of 2.53 and P/S of 0.19, while recent earnings beat expectations in Q1 and Q2 2026. Revenue grew to $1.62B in 2024 with net income margin improving to 7.61% in 2025 projections. Analyst consensus is bullish with a $15.33 price target and no sell ratings among 15 analysts covering the stock.
FUBO presents a compelling turnaround story with improving profitability and attractive valuation. The company's partnership with Disney/Hulu and sports content focus drives growth potential, though negative cash flow and high debt levels remain concerns. With 47% analyst buy ratings and 53% upside to consensus target, the stock offers significant potential if execution continues improving.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
